In a recent report, Stifel analysts gave their bullish analysis of several stocks. Here’s a breakdown of what the analysts had to say about three of their Buy-rated names.
Jazz Pharmaceuticals plc JAZZ 0.95%
Analysts see “blockbuster potential” for Jazz’s defibrotide drug that Jazz acquired full rights to in 2014. The drug, used to treat hepatic veno-occlusive disease, has already launched in Europe and is working its way down the U.S. regulatory pathway.
Analysts believe that that defibrotide will see expanded uses in the future and that the drug could eventually surpass the value of Jazz’s flagship drug, Xyrem.
Analysts feel that the market is not fully appreciating the potential of defibrotide, and they name Jazz as a top pick and place a $225.00 target on the stock.
Norwegian Cruise Line Holdings Ltd NCLH 1.32%
The major case analysts make for Norwegian Cruise Line is a valuation case. Analysts note that the stock currently trades at just about 12x their 2016 earnings per share estimates for the company. Stifel is predicting 20 percent earnings growth for the company in each of the next three years.
Norwegian Cruise’s stock jumped by more than 7 percent on Wednesday after Tuesday’s earnings beat, and Stifel sees more even more upside to come.
The firm has a Buy rating on the stock and a $49.00 price target.
WellCare Health Plans, Inc. WCG 2.28%
After a shaky past that includes wild swings in share price, an FBI raid and other drama, Stifel analysts are convinced that WellCare finally has a management team that understands the importance of both executing the company’s business plan and communicating clearly with shareholders.
Analysts predict that WellCare’s revenue and earnings will double in the next few years.
Stifel currently has a Buy rating on WellCare and a $100.00 price target on the stock.
Read this article and all my other articles for free on Benzinga by clicking here
Want to learn more about the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!
